VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds Purchases 181,818 Shares

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds acquired 181,818 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the acquisition, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. The trade was a 8.59 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

VolitionRx Stock Up 4.9 %

VNRX stock traded up $0.03 during trading on Thursday, reaching $0.54. The company’s stock had a trading volume of 117,989 shares, compared to its average volume of 177,031. The company’s fifty day moving average is $0.59 and its 200-day moving average is $0.64. VolitionRx Limited has a 1 year low of $0.43 and a 1 year high of $1.02. The company has a market capitalization of $50.04 million, a P/E ratio of -1.50 and a beta of 1.09.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VNRX. Lagoda Investment Management L.P. boosted its holdings in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. Geode Capital Management LLC grew its stake in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Northern Trust Corp raised its holdings in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. Millennium Management LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at about $36,000. Finally, Two Sigma Securities LLC acquired a new position in VolitionRx during the 4th quarter valued at approximately $29,000. Institutional investors own 8.09% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. D. Boral Capital reissued a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research report on Thursday, March 20th. StockNews.com initiated coverage on VolitionRx in a research report on Thursday, March 20th. They issued a “sell” rating for the company.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.